Malignant pleural mesothelioma

Vogelzang, N.J. et al.. Phase III study of pemetrexed in combination with cisplatm versus cis-platin alone in patients with malignant pleural mesothelioma, /. Clin. Oncol, 21, 2636-2644, 2003. [Pg.455]

Pemetrexed is chemically similar to folic acid. It inhibits three enzymes used in purine and pyrimidine synthesis - thymidylate synthetase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase. By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA. In 2004 it was approved for treatment of malignant pleural mesothelioma and as a second-line agent for the treatment of non-small cell lung cancer. Adverse effects include gastrointestinal complaints, bone marrow suppression, alopecia, allergic and neurotoxic reactions. [Pg.452]

Frebourg, T. et al., Serum hyaluronate in malignant pleural mesothelioma, Cancer, 59, 2104, 1987. [Pg.270]

Zanellato I, Heldt J-M, Vessieres A, Jaouen G, Osella D (2009) Antiproliferative effect of ferrocifen drug candidates on malignant pleural mesothelioma cell lines. Inorg Chim Acta 362 4037 1042... [Pg.116]

Bianchi C, Brollo A, Ramani L, et al. 1997. Pleural plaques as risk indicators for malignant pleural mesothelioma A necropsy-based study. Am J Ind Med 32 445-449. [Pg.237]

Booth SJ, Weaver EJ. 1986. Malignant pleural mesothelioma five years after domestic exposure to blue asbestos [Letter], Lancet 1 435. [Pg.239]

Cazzadori A, Malesani F, Romeo L. 1992. Malignant pleural mesothelioma caused by non-occupational childhood exposure to asbestos. Br J hid Med 49 599... [Pg.243]

Chailleux E, Pioche D, Chopra S, et al. 1995. [The epidemiology of malignant pleural mesothelioma in the Nantes-Saint-Nazaire region. Evolution between 1956 and 1992]. Rev Mai Resp 12 353-357. [Pg.243]

Erzen C, Eryilmaz M, Kalyoncu F, et al. 1991. CT findings in malignant pleural mesothelioma related to nonoccupational exposure to asbestos and fibrous zeolite (erionite). J Comput Assist Tomogr 15 256-260. [Pg.263]

Huncharek M, Kelsey K, Muscat J, et al. 1996. Parental cancer and genetic predisposition in malignant pleural mesothelioma A case-control study. Cancer Lett 102 205-208. [Pg.279]

Kawai A, Nagasaka Y, Muraki M, et al. 1997. Brain metastasis in malignant pleural mesothelioma. [Pg.287]

McLean AN, Patel KR. 1997. Clinical features and epidemiology of malignant pleural mesothelioma in west Glasgow 1987-1992. Scott Med J 42 37-39. [Pg.301]

Metintas M, Ozdemir n, Hillerdal G, et al. 1999. Environmental asbestos exposure and malignant pleural mesothelioma. Resp Med 93 349-355. [Pg.302]

Pass HI. 1994. Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma. Chest Surg Clin N Am 4 497-515. [Pg.316]

Sahin AA, Coplii L, Selcuk ZT, et al. 1993. Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey CT findings in 84 patients. AJR Am J Roentgenol 161(3) 533-537. [Pg.325]

Sakellariou K, Malamou-Mitsi V, Haritou A, et al. 1996. Malignant pleural mesothelioma from nonoeeupational asbestos exposure in Metsovo (north-west Greeee) Slow end of an epidemic Eur Resp J 9 1206-1210. [Pg.325]

Segers K, Ramael M, Singh SK, et al. 1995. Detection of numerical chromosomal aberrations in paraffin-embedded malignant pleural mesothelioma by non-isotopic in situ hybridization. J Pathol 175 219-226. [Pg.328]

Selcuk ZT, Coplii E, Emri S, et al. 1992. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey Analysis of 135 cases. Chest 102(3) 790-796. [Pg.328]

Shepherd KE, Oliver EC, Kazemi H. 1989. Difiuse malignant pleural mesothelioma in an urban hospital Clinical spectrum and trend in incidence over time. Am J Ind Med 16 373-383. [Pg.329]

Shin DM, Fossella FV, Umsawasdi T, et al. 1995. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76 2230-2236. [Pg.329]

Luce D, Brochard P, Quenel P, et al. 1994. Malignant pleural mesothelioma associated with exposure to tremolite. Lancet 344 1777. [Pg.436]

Indications Malignant pleural mesothelioma Category Folic acid antagonist Half-life 3.5 hours... [Pg.443]

Walz R, Koch HK. Malignant pleural mesotheliomas Some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985. Pathol Res Pract. 1990 186 124-134. [Pg.459]

Brown RW, Clark GM, Tandon AK, et al. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol. 1993 24 347-354. [Pg.459]

Kawai T, Suzuki M, Torikata C, et al. Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma. Hum Pathol. 1991 22 118-124. [Pg.460]

Okamoto H, Matsuno Y, Noguchi M, et al. Malignant pleural mesothelioma producing chorionic gonadotropin Report of two cases. Am J Surg Pathol. 1992 16 969-974. [Pg.461]

Pemetrexed is a folic-acid antagonist that disrupts folate-dependent metabolic processes essential for cell replication. It is indicated in combination with cisplatin for the treatment of malignant pleural mesothelioma in patients whose disease is unresectable or who are otherwise not candidates for curative surgery and as a single agent for the treatment of locally advanced or metastatic non-small-cell lung cancer after prior chemotherapy. [Pg.552]

Pemetrexed (Fig. 42.25) is a novel multitarget antifolate used by the IV route for the treatment of advanced or metastatic nonsmall cell lung cancer and in combination with cisplatin in malignant pleural mesothelioma. [Pg.1819]

Isik, R., Metintas, M., Gibbs, A.R., Metintas, S., Jasani, B., Oner, U., Harmanci, E., Demircan, S., and Isiksoy, S., p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure, Respir. Med., 95, 588-593,2001. [Pg.72]

Anraku M et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008 135 823-829. [Pg.392]

Galffy G, Mohammed KA, Nasreen N, Ward MJ, Antony VB. Inhibition of interleu-kin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. Oncol Res 1999 11 187-194. [Pg.338]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...